Related Experiment Video
Updated: Jan 18, 2026
05:10
Multidisciplinary Approach to Obesity Management: A Case Report
Published on: May 30, 2025
913
Health and Well-Being Coaching Adjuvant to GLP-1 Induced Weight Loss
Gary A Sforzo1, Neil F Gordon2, Pamela M Peeke3
1School of Health Science and Human Performance, Ithaca College, Ithaca, NY, USA (GAS).
American Journal of Lifestyle Medicine
|November 22, 2024
Summary
Health and well-being coaching (HWC) may improve adherence and sustain weight loss for patients using glucagon-like peptide-1 (GLP-1) agonists. This coaching approach can help manage side effects and promote lasting healthy behaviors.
Area of Science:
- Obesity Medicine
- Behavioral Science
Background:
- Glucagon-like peptide-1 (GLP-1) agonists are effective anti-obesity medications.
- Challenges include poor adherence, resumption of old behaviors, and side effects like gastrointestinal distress.
- Health and well-being coaching (HWC) is a recognized intervention for obesity management.
Purpose of the Study:
- To explore the potential benefits of integrating HWC with GLP-1 agonist prescriptions.
- To investigate how HWC can improve medication adherence and promote sustained weight loss.
- To examine HWC's role in managing GLP-1 related side effects and promoting healthy behaviors.
Main Methods:
- The study proposes a patient-centric, collaborative coaching model.
- Specific coaching techniques are suggested for patients undergoing rapid weight loss.
- The approach emphasizes understanding the complexities of GLP-1 therapy.
Main Results:
- HWC is expected to improve patient adherence to GLP-1 medications.
- Coaching may help patients persist with treatment and navigate side effects.
- The intervention aims to encourage sustained weight loss and overall health benefits.
Conclusions:
- HWC shows promise as an adjuvant therapy for GLP-1 prescriptions in obesity.
- A collaborative coaching relationship is crucial for treatment success.
- Further research is needed to validate the effectiveness of HWC in this context.
More Related Videos
06:13Author Spotlight: Exploring the Impact of Reduced Resistance Exercise Volume on Metabolic Health
Published on: December 1, 2023
1.6K
03:05Influence of Emotional Factors on the Efficacy of Acupuncture Treatment for Overweight Complicated with Hyperlipidemia: A Retrospective Cohort Study
Published on: November 21, 2025
484
Related Concept Videos
01:24Glucagon-like Receptor Agonists
854
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
854
01:16Hormones Regulating Blood Glucose
6.5K
Insulin is released by beta cells of the pancreas when blood glucose levels are high. It facilitates glucose absorption and utilization in insulin-dependent cells with insulin receptors on their plasma membranes. Insulin promotes glucose uptake by increasing the number of glucose transport proteins in the cell membrane, allowing glucose to enter the cell. As a result, glucose utilization and ATP production are enhanced.
In addition to accelerating glucose uptake and utilization, insulin has...
In addition to accelerating glucose uptake and utilization, insulin has...
6.5K
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
526
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
526
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
588
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
588
01:06Oral Hypoglycemic Agents: Glinides
601
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
601
01:23Dipeptidyl Peptidase 4 Inhibitors
598
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
598